1[1]Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995, 1: 27～31.
2[2]Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcino genesis in mice. Science, 1999, 284: 808～812.
3[3]Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res, 2000, 60: 203212.
4[4]Eliceiri BP, Cheresh DA. The role of alphav integrins dur ing angiogenesis: insights into potential mechanisms of ac tion and clinical development. J Clin Invest, 1999, 103:1227～1230.
5[5]Iljin K, Karkkainen MJ, Lawrence EC, Kimak MA, Uutela M, Taipale J, Pajusola K, Alhonen L, Halmekyto M, Finegold DN, Ferrell RE, Alitalo K. VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J, 2001, 15: 1028～1036.
6[6]Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-l-deficient mice. Nature, 1995, 376: 62～66.
7[7]Shibuya M. Structure and function of VEGF/VEGF-recep tor system involved in angiogenesis. Cell Struct Funct,2001, 26: 25～35.
8[8]Hidaka M, Stanford WL, Bernstein A. Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc Natl Acad Sci U S A, 1999, 96: 7370～7375.
9[9]Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt l lacking the tyrosine kinase domain is sufficient for nor mal development and angiogenesis in mice. Proc NatlAcad Sci U S A, 1998, 95: 9349～9354.
10[10]Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Musto nen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science, 1998, 282: 946～949.
